Theravance Biopharma CFO Andrew Hindman to depart Dec 31; Aziz Sawaf named successor

Theravance Biopharma, Inc.

Andrew Hindman, SVP and CFO, will leave on December 31, 2022.
Aziz Sawaf appointed CFO effective Jan 1, 2023; previously VP of Finance since Oct 2021.
Sawaf joined Theravance in 2014; prior roles at Gilead Sciences, Amgen, and consulting.
Sawaf holds CFA charter, MBA from USC, and MBEE from Johns Hopkins University.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Andrew A. Hindman

Senior Vice President and Chief Financial Officer

TBPH · Theravance Biopharma, Inc.

Effective: 2022-12-31
Successor: Aziz Sawaf
Filed: December 12, 2022, 6:59 PM ET

Andrew A. Hindman, Senior Vice President and Chief Financial Officer, will transition from the Company on December 31, 2022.

Appointed

Aziz Sawaf

Chief Financial Officer

TBPH · Theravance Biopharma, Inc.

Effective: 2023-01-01
Filed: December 12, 2022, 6:59 PM ET

The Company has appointed Aziz Sawaf, CFA as the Company’s Chief Financial Officer, effective immediately following Mr. Hindman’s departure.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Andrew A. Hindman changed role as Senior Vice President and Chief Financial Officer at Theravance Biopharma, Inc..

Action: will transition
Role: Senior Vice President and Chief Financial Officer

Exact text from the filing

Andrew A. Hindman, Senior Vice President and Chief Financial Officer, will transition from the Company on December 31, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Aziz Sawaf was appointed as Chief Financial Officer at Theravance Biopharma, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

The Company has appointed Aziz Sawaf, CFA as the Company’s Chief Financial Officer, effective immediately following Mr. Hindman’s departure.

View on SEC.gov

Theravance Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-126067

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.